{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "MEDP",
  "name": "Medpace Holdings, Inc.",
  "url": "https://orbyd.app/dossiers/MEDP/",
  "json_url": "https://orbyd.app/dossiers/MEDP.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a2",
    "n": 2
  },
  "current_thesis": "Biotech-funding-recovery narrative re-accelerating through the CRO channel: Q2 (2026-07-22) new business awards +28.2% YoY to $795.7M, book-to-bill 1.13x, and FY26 revenue AND EPS guides both raised. The buyable leg is a bookings inflection into 2027 revenue; the risk is chasing a day-3 post-print gap while sell-side sits split (three Hold/Neutral vs two Outperform).",
  "invalidation_trigger": "A weekly close below $560 fills the July 2026 earnings gap and breaks the post-print momentum leg; secondary next-quarter net book-to-bill slipping back under 1.10x, or the theme flipping to SATURATED.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q2 FY26 printed 2026-07-22 (EPS $4.25 vs $3.97; rev $707.3M vs $687.6M); next quarterly Q3 est ~late-Oct 2026 no earnings blackout inside 30d.",
    "Post-print PT cluster (2026-07-24): RBC $692, Mizuho $665, Baird $624, Truist $609, BMO $600 sell-side split 2 Outperform / 3 Hold-Neutral.",
    "Archetype = picks-and-shovels toll-taker on small/mid biotech R&D; reads with XBI/biotech financing window, inverse to real rates.",
    "Price levels inferred from PT structure (no live price context supplied) re-anchor the $560 gap-fill level against actual post-earnings candles on next refresh."
  ],
  "body_markdown": "## Current Thesis\nMedpace is the owner-operated, single-shop CRO levered to small- and mid-cap biotech the toll-taker on drug-development spend rather than a bet on any one molecule. The buyable leg is a bookings inflection: the 2026-07-22 Q2 print put new business awards at $795.7M (+28.2% YoY), net book-to-bill back to 1.13x, and management raised both the FY26 revenue and EPS floors. Bookings lead CRO revenue by 12-18 months, so the print is an early read on 2027 numbers. The live tension is that this is confirmation of a known 2026 recovery arriving into a day-3 post-earnings gap, with sell-side still split.\n\n## Bull Case\n- Q2 EPS $4.25 vs $3.97 est and revenue $707.3M vs $687.6M est (2026-07-22) a clean top and bottom-line beat, not a tax-line beat.\n- New business awards $795.7M, +28.2% YoY, net book-to-bill 1.13x (2026-07-22). Bookings are the leading indicator for a CRO; a >1.1x ratio alongside 28% award growth means backlog is still compounding.\n- FY26 guidance raised on both lines (2026-07-22): revenue to $2.805-2.885B (from $2.755-2.855B) vs $2.778B est; GAAP EPS to $17.25-17.95 (from $16.68-17.50) vs $16.97 est. Management lifts the floor only when demand visibility has firmed.\n- PT ladder stepped up hard post-print (2026-07-24): RBC Outperform $692, Mizuho Outperform $665 (from $586 on 07-13), Baird Neutral $624 (from $547 on 07-08), Truist Hold $609, BMO $600.\n- Structural leverage: as the pure-play on small/mid biotech, Medpace's RFP flow converts directly off a reopening biotech financing window the segment most sensitive to a funding thaw.\n\n## Bear Case\n- The theme reads MATURING. \"Precision-biotech-therapeutics\" is a known 2026 recovery cohort; the Q2 beat confirmed the direction rather than surprising anyone on it.\n- Sell-side hasn't converted: three of the five recent actions are Hold/Neutral (Baird downgraded to Neutral 07-08, BMO Market Perform, Truist Hold). The consensus is not a buyers' consensus.\n- Entry timing is a chase the stock soared on the beat (2026-07-23), so buying here buys the gap, not the base. CRO compounders routinely mean-revert to moving-average support after an earnings pop.\n- Book-to-bill of 1.13x is healthy but not euphoric. One soft cancellation quarter the exact failure mode of the 2023-24 biotech winter drags it back under 1.10x and stalls the acceleration story.\n- Macro headwind to the customer base: the same 2026-07-23 tape carried the 10-year at an 18-month high and Brent over $100. Rising real rates raise small-biotech cost of capital and, with a lag, throttle RFP flow.\n\n## Setup & Price Structure\nPost-earnings gap-up off the 2026-07-22 print. The analyst PT cluster $600-692 brackets the current zone: Neutral/Hold desks anchor $600-624 (targets that typically sit at-or-just-above spot), and the RBC bull case at $692 implies only moderate headroom. Structure is extended the name just cleared a pre-print shelf that pre-earnings targets marked around $547-586. The disciplined continuation entry is a pullback into the rising 20-EMA / gap-fill zone rather than the day-3 chase. Strength on the print is confirmation of the bookings inflection, but for a maturing-theme compounder the reward/risk on a gap chase is thin until it bases.\n\n## Catalyst Calendar (next 30 days)\n\n- Macro read-through is the live daily driver: 10-year yield prints and biotech-financing-window headlines (XBI action) move the customer base directly.\n\n## Elapsed catalysts\n\n- No company-dated binary inside the window: Q2 already printed 2026-07-22; the next quarterly (Q3) is est. ~late-October 2026, outside 30 days. _(passed 4d ago)_\n- Post-earnings analyst revisions still trickling (cluster hit 2026-07-24) a bulge-bracket Hold→Buy flip would convert the split sell-side and signal the narrative going mainstream. _(passed 2d ago)_\n\n## What Would Change Our Mind\n- A weekly close below $560 fills the July 2026 earnings gap and breaks the post-print momentum leg the clean structural invalidation for a continuation buyer.\n- Bookings roll-over: next print's net book-to-bill back under 1.10x, or a return to declining net awards, kills the re-acceleration thesis regardless of price.\n- Theme flip: precision-biotech-therapeutics tipping from MATURING to SATURATED peak mainstream CRO coverage with no new financing catalyst turns post-print strength into distribution.\n\n## Correlation Notes\n- Tracks the biotech-funding cycle: XBI/IBB and small-cap biotech financing volume are the upstream driver; MEDP collects the toll on whatever gets funded.\n- CRO peer set (ICLR, IQV) runs adjacent, but Medpace is the small-biotech pure-play. MEDP's book-to-bill outrunning the peers' would confirm the funding thaw is broad.\n- Inverse to real rates: the rising 10-year (18-month high, 2026-07-23) pressures the biotech customer's cost of capital and, with a lag, the RFP pipeline that feeds bookings.",
  "first_seen": "2026-07-24",
  "last_analyzed": "2026-07-25T07:21:42+00:00",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}